Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients With Nonvalvular Atrial Fibrillation - SPORTIF III

Description:

The goal of the Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients With Nonvalvular Atrial Fibrillation (SPORTIF III) trial was to determine the safety and efficacy of a novel, oral direct thrombin inhibitor ximelagatran versus warfarin for prevention of stroke and systemic embolic events in patients with atrial fibrillation (AF) and at least one additional risk factor for stroke.